Last reviewed · How we verify
NCT03782025: VITAKOAG
Effect of Vitamin K in Critically Ill Patients
trial testing Phytomenadione in Coagulation Factor Deficiency in 52 participants. Completed in 20 March 2020.
20 March 2020
Quick facts
| Lead sponsor | Region Skane |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 52 |
| Start date | 13 February 2019 |
| Primary completion | 20 March 2020 |
| Estimated completion | 20 March 2020 |
| Sites | 2 locations across Sweden |
Drugs / interventions tested
- Phytomenadione — full drug profile →
Conditions studied
- Coagulation Factor Deficiency — all drugs for Coagulation Factor Deficiency →
- Coagulopathy, Consumption — all drugs for Coagulopathy, Consumption →
- Vitamin K Deficiency — all drugs for Vitamin K Deficiency →
Sponsor
Region Skane — full company profile →
Who can join
18 and older, any sex, with Coagulation Factor Deficiency or Coagulopathy, Consumption. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Critically ill patients with spontaneously prolonged pro-thrombin time, where administration of intravenous administration of phytomenadione (vitamin K) has been ordered by the treating physician will be identified. After signed informed consent baseline samples will be collected. Phytomenadione will be given and 24 hours after administration new blood samples will be collected. Several different advanced coagulation and vitamin K-assays will be performed before and 24 hours after vitamin K administration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03782025
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coagulation Factor Deficiency
Currently open trials in the same condition.
- NCT06727669 — Longitudinal Cohort of Thrombosis and Hemostasis Diseases · recruiting
- NCT06481995 — SWIFT - SWIss Factor XIII Trial in PPH · Phase 4 · recruiting
Other Region Skane trials
Trials by the same sponsor.
- NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D · NA · not yet recruiting
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery · not yet recruiting
- NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
- NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03782025 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Skane
- Last refreshed: 18 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03782025.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing